To know the effect of Virechana with Vardhamana Pippali Rasayana and compare it with another group of Basti Karma with Vardhamana Pippali Rasayana in the patients of Amavata (Rheumatoid Arthritis)

Study on the efficacy of Virechana with Vardhamana Pippali Rasayana in comparison to the efficacy of Basti Karma with Vardhamana Pippali Rasayana in the management of Amavata (Rheumatoid Arthritis) - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/073922

Enrollment

Registered

2024-09-13

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of all genders between 21 and 60 years. 2. Having classical features of Amavata like Angamarda(malaise), Aruchi(Anorexia), Trishna (excessive thirst), Alasya(laziness), Gaurava(heaviness of body), Jwara(fever), Apaka(indigestion), Angashoonata(swelling). 3. Diagnosed cases of Amavata(RA). 4. Who are taking anti-inflammatory(analgesics)/steroids will be included after a washout period of 7 days provided, they are diagnosed with RA in the last 1 year. 5. Patients fulfilling 2010 ACR (American College of Rheumatology)/EULAR (European League against Rheumatism) criteria for rheumatoid arthritis. 6. Patients willing to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Patients with other systemic complications of RA like RHD, Rheumatic fever, pleural-pericardial disease. 2. Patients with Grade II Hypertension (more than 160/100 mm of Hg) or more. 3. Patients with Diabetes Mellitus, Hypothyroidism. 4. Patients diagnosed with other arthritis like osteoarthritis, gouty arthritis, tuberculous arthritis. 5. Who are unable to walk without support or confined to a wheelchair. 6. H/o hypersensitivity to any of the trial drugs or their ingredients. 7. Patients on prolonged (more than 6 weeks) medication with antidepressants, anticholinergic, etc. or any other drugs that may have an influence on the outcome of the study. 8. Pregnant / lactating women. 9. Who have completed participation in any other clinical trial during the past 6 months. 10. Patients having Anemia (Hb below 8gm/dl). 11. Patients having Polycystic ovary syndrome (PCOS).

Design outcomes

Primary

Measure	Time frame
To assess the improvement in cardinal symptoms of Amavata (RA) –ruja(pain), shoth (swelling), sparshasahata(tenderness) and Stabdhata (stiffness).Timepoint: Baseline After 15 days AFTER 35 days	—

Secondary

Measure	Time frame
To improve the quality of life of Amavata patients.Timepoint: Baseline After 15 days After 35 days	—

Countries

India

Contacts

Public ContactProf Dr Jonah S

All India Institute of Ayurveda

jonahdr@gmail.com9448262298

Outcome results